Overview
- TRIUMPH-4 ran 68 weeks and randomized 445 adults with overweight or obesity and knee osteoarthritis to once‑weekly 9 mg or 12 mg retatrutide versus placebo.
- The 12 mg dose yielded 28.7% mean weight loss for on‑treatment patients (about 71 pounds on average) and 23.7% when including discontinuations, with more than half on 12 mg losing at least 25%.
- Knee pain on the WOMAC scale fell substantially, with up to 62.6% average reduction across all treated patients and more than one in eight reporting no knee pain by week 68.
- Adverse events were largely gastrointestinal; dysesthesia occurred in up to 20.9% at 12 mg, and discontinuations were higher with retatrutide (12.2%–18.2% vs 4% on placebo), including some who stopped for perceived excessive weight loss.
- The once‑weekly GIP/GLP‑1/glucagon “triple‑G” mechanism distinguishes retatrutide from current therapies, and analysts said the results raise the bar for obesity drug competitors such as Novo Nordisk.